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Abstract
Background Combined ‘hybrid’ thoracoscopic and
percutaneous atrial fibrillation (AF) ablation is a strat-
egy used to treat AF in patients with therapy-resistant
symptomatic AF. We aimed to study efficacy and
safety of single-stage hybrid AF ablation in patients
with symptomatic persistent AF, or paroxysmal AF
with failed endocardial ablation, and assess determi-
nants of success and quality of life.
Methods We included consecutive patients under-
going single-stage hybrid AF ablation. First, we per-
formed epicardial ablation, via thoracoscopic access,
to isolate the pulmonary veins and superior caval vein
and to create a posterior left atrial box. Thereafter,
isolation was assessed endocardially and complemen-
tary endocardial ablation was performed, followed by
cavotricuspid isthmus ablation. Efficacy was assessed
by 12-lead electrocardiography and 72-hour Holter
monitoring after 3, 6 and 12 months. Recurrence was
defined as AF/atrial flutter/tachycardia recorded by
electrocardiography or Holter monitoring lasting >30s
during 1-year follow-up.
Results Fifty patients were included, 57± 9 years, 38
(76%) men, 5 (10%) paroxysmal, 34 (68%) persistent
and 11 (22%) long-standing persistent AF. At 1-year
38 (76%) maintained sinus rhythm off antiarrhyth-
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mic drugs. Majority of recurrences were atrial flutter
(9/12 patients). Success was associated with type
of AF (p= 0.039). Patients with paroxysmal AF had
highest success, patients with longstanding persis-
tent AF had lowest success. Seven (14%) patients
had procedure-related complications. Quality of life
improved after ablation in patients who maintained
sinus rhythm.
Conclusion Success of single-stage hybrid AF ablation
was 76% off antiarrhythmic drugs, being associated
with type of AF. Quality of life improved significantly,
Procedure-related complications occurred in 14%.
Keywords Atrial fibrillation · Hybrid · Ablation · Tho-
racoscopic · Pulmonary vein isolation · Single-stage
Introduction
At present there is only limited evidence that a rhythm
control strategy for atrial fibrillation (AF) improves pa-
tients‘ mortality and morbidity [1–4]. However, many
patients are moderately to severely symptomatic, ne-
cessitating a rhythm control strategy [5].
Antiarrhythmic drugs (AADs), often being used as
first-line rhythm control strategy [5], are only moder-
ately successful in maintaining sinus rhythm (SR) dur-
What’s new?
 Single-stage hybrid ablation is highly effective in
patients with paroxysmal AF after prior failed en-
docardial ablations.
 Type of AF is the main determinant of sin-
gle-stage hybrid ablation success.
 Hybrid AF ablation led to improvement in pa-
tients’ quality of life.
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ing long-term follow-up [6]. Endocardial pulmonary
vein isolation (PVI) has now become an established,
effective and safe therapy for patients with paroxys-
mal AF [5, 7]. However, in patients with persistent and
long-standing persistent AF, PVI alone is less effective,
even after multiple procedures [8], or with the inclu-
sion of additional endocardial ablation lines or targets
[9]. This is likely due to advanced electro-anatomic re-
modelling of the atria and the extra-pulmonary vein
triggers being more prominent [10].
The surgical Cox-Maze procedure showed higher
success in patients with persistent and long-standing
persistent AF [11]. It is, however, a complex and inva-
sive procedure. Hybrid AF ablation combines surgical
thoracoscopic epicardial atrial ablation with endocar-
dial atrial catheter ablation. The potential benefit of
this combined approach is that incomplete epicardial
ablation lines can be completed in the same session,
via an endocardial approach. In contrast to the Cox-
Maze procedure, thoracoscopic epicardial ablation is
less invasive. At present, there is still little data about
the outcome of single-stage hybrid AF ablation with
few centres reporting conflicting results [12, 13]. Our
aim is to investigate the efficacy and safety of hybrid
AF ablation at our centre, to explore factors determin-
ing its success, and to assess its effect on the quality
of life.
Fig. 1 The standard set
of ablation lines during the
hybrid AF ablation proce-
dure (White lines epicardial
lines, yellow dotted lines en-
docardial lines; AF atrial
fibrillation, LA left atrium,
RA right atrium, LSPV left
superior pulmonary vein,
LIPV left inferior pulmonary
vein, RSPV right superior
pulmonary vein, RIPV right
inferior pulmonary vein,
CTI cavotricuspid isthmus,
SVC superior caval vein,
IVC inferior caval vein)
Methods
Patient population
The Hybrid AF Ablation study, Clinicaltrials.gov reg-
istration number NCT02516033, is a prospective, sin-
gle-centre, observational study performed at the Uni-
versity Medical Center Groningen, the Netherlands.
A total of 50 consecutive patients were included be-
tween January 2015 and June 2016. The institutional
review board approved the study protocol, and all pa-
tients provided written informed consent. Patients
with symptomatic persistent or long-standing persis-
tent AF, or paroxysmal AF with two or more failed
catheter ablations were candidates for this procedure.
Patients with a history of cardiac surgery, and patients
with a body mass index (BMI) of 35 or over were ex-
cluded.
Definitions
AF was defined as paroxysmal (all AF episodes lasting
less than 7 consecutive days), persistent (at least some
AF episodes lasting more than 7 consecutive days, but
could still spend periods in SR), or long-standing per-
sistent AF (AF episode lasting more than 365 consec-
utive days) [5].
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Table 1 Patient clinical characteristics of study popula-
tion at baseline (n= 50)
age (years) 57± 9






previous failed catheter ablation(s) 25 (50%)
previous CTI ablation 10 (20%)
heart failure 2 (4%)
hypertension 23 (46%)
diabetes mellitus 4 (8%)
coronary artery disease 2 (4%)
stroke or TIA 3 (6%)
CHA2-DS2-VASc score 1 (0–2)
physical examination
systolic blood pressure (mmHg) 129± 14
diastolic blood pressure (mmHg) 82± 10
BMI (kg/m2) 28.0± 3.8
obesity (BMI> 30) 12 (24%)
echocardiography
interventricular septum thickness (mm) 10.6± 1.9
LA volume index (ml/m2) 40± 11
LVEF (%) 55± 6
use of antiarrhythmic drugs 19 (38%)
AF atrial fibrillation, CHA2-DS2- congestive heart failure, hypertension,
age≥ 75 years [doubled], diabetes mellitus, prior stroke [doubled]-vascular
disease age 65–74, sex category, CTI cavotricuspid isthmus, TIA transient
ischaemic attack, BMI body mass index, LA left atrial, LVEF left ventricular
ejection fraction
Study design
At baseline, we assessed clinical history, physical ex-
amination, current medication, an electrocardiogram,
blood samples, 24-hour Holter monitoring, echocar-
diography, cardiac computed tomography scan and
quality of life.
Prior to the procedure, a trans-oesophageal echocar-
diogram was performed to exclude the presence
of a thrombus in the left atrium and atrial ap-
pendage. Outpatient clinic visits with electrocardiog-
raphy (ECG) recording were scheduled at 1, 3, 6 and
12 months after procedure. At 3, 6 and 12 months,
a 72-hour Holter monitoring was performed. At
12 months, quality of life was re-assessed. During
all visits we collected information about AF, atrial
flutter (AFL) or atrial tachycardia (AT) recurrences
documented by the general practitioner, during emer-
gency room visits or during hospital admissions, as
well as adverse events associated with the proce-
dure. AADs were continued during the first 3 months,
and then discontinued in symptom-free patients. All
patients were on acenocoumarol treatment for at
Table 2 Procedural data
all patients (n= 50)
rhythm at start of procedure
– SR 22 (44%)
– AF 28 (56%)
total procedure time (minutes) 396± 45
surgical part
– patient preparation (minutes) 55± 12
– surgical procedure (minutes) 218± 47
– percutaneous part (minutes) 128± 36
total number of epicardial applications 85± 27
– right pulmonary veins 8± 2
– left pulmonary veins 8± 3
– superior line 28± 13
– inferior line 34± 16
– superior caval vein 2± 1
patients undergoing endocardial ablation: 48 (96%)
– to complete box isolation 21 (42%)
– for CTI line 41 (82%)
– for additional lines (to stop AFL/AT) 19 (38%)
– for CFAE ablation (to stop AF) 22 (44%)
confirmed box isolation after epicardial
ablationa
27 (54%)
LAA closure 15 (30%)
CTI cavotricuspid isthmus, SR sinus rhythm, AF atrial fibrillation, AFL atrial
flutter, AT atrial tachycardia, CFAE complex fractionated atrial electrogram,
LAA left atrial appendage
a through endocardial electrophysiological mapping
least 4 weeks before the procedure. Periprocedurally,
acenocoumarol was not interrupted (target interna-
tional normalised ratio (INR) 2–2.5) and continued
thereafter for at least 3 months.
Hybrid AF ablation procedure
The procedure was performed under general anaes-
thesia. A double lumen endotracheal tube was placed
for selective lung ventilation.
Thoracoscopic procedure
Three thoracoscopic ports were placed on the right
side, one 5-mm camera port at the fifth intercostal
space (midaxillary) and two working ports in a dia-
mond shape, 5-mm and 12-mm, respectively. After-
wards, the pericardium was opened anterior to the
phrenic nerve. The transverse and oblique sinuses
were opened with blunt dissection. A track light dis-
sector (Lumitip, AtriCure) was then used to guide
a rubber band and position the ablation device (Iso-
lator Synergy Clamps, AtriCure) around the right
pulmonary veins (PVs). We ablated the right PVs and
then performed ablation of the superior caval vein,
using the same bipolar clamp. Ablation for the roof
and inferior line of the posterior left atrial box was
performed using a linear ablation device (Coolrail,
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Fig. 2 Flow chart showing
the steps followed during
the procedure for the pa-
tients in the study cohort.
aThe surgeon couldn’t gain
access to the left atrium
from the right side be-
cause of local adhesions.
bIn patients with previ-
ous catheter CTI ablation.
(LPV left pulmonary vein,
SVC superior caval vein,
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AtriCure). We tested isolation of the right PVs and the
superior caval vein epicardially with a 4-polar catheter
(Supreme, St. Jude Medical), with additional ablation
if necessary. The left PVs were ablated via a similar left
thoracoscopic approach. To complete the posterior
box, the roof and inferior line were also made from
the left side meeting the ablation lines made from
the right side. The isolation of the ablated structures
(including the box) was tested again. In patients with
previous catheter PV ablation, we tested PV isolation
epicardially with the 4-polar Supreme catheter before
ablation, but performed epicardial ablation irrespec-
tive of whether the PVs were isolated or not. Finally, in
patients with CHA2DS2-VASc (congestive heart failure,
hypertension, age ≥75 [doubled], diabetes mellitus,
prior stroke [doubled]-vascular disease, age 65–74,
sex category) scores of 2 or higher, we performed
surgical exclusion of the left atrial appendage (LAA),
using a minimally invasive occlusion device (AtriClip,
AtriCure). LAA exclusion did not involve any ablation
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Table 3 Results after 1-year follow-up. Success at 1-year
follow-up
all patients (n= 50)
sinus rhythm maintenancea 38 (76%)
total recurrences 12 (24%)
– atrial fibrillation recurrences 3 (6%)
– atrial flutter recurrences 9 (18%)
antiarrhythmic drug use at 1 year 2 (4%)
endocardial re-ablation 7 (14%)
electrical or chemical cardioversion 9 (18%)
a Off antiarrhythmic drugs and without re-ablation
and was performed exclusively for stroke reduction.
Oral anticoagulants were resumed after the procedure
in all patients according to their CHA2DS2-VASc score,
regardless of undergoing LAA exclusion [5].
Percutaneous procedure
After the surgical procedure, access to the left atrium
was established via the femoral vein with a single
trans-septal puncture using an 8.5F sheath (Agilis
steerable sheath, St. Jude Medical), after which
100E/kg bolus dose of unfractionated heparin was
given (target activating clotting time >300s). Three
dimensional electroanatomical mapping was per-
formed using NavX Ensite Velocity (NavX, St. Jude
Medical). Electroanatomical maps of the left atrium
were created with a circular multipolar catheter (In-
quiry optima or Inquiry AFocusII, St. Jude Medical).
We performed ablation with an open irrigated 4mm
tip contact force ablation catheter (TactiCath Quartz
CF ablation catheter, St. Jude Medical). We performed
additional endocardial ablation if the veins were not
isolated, surgical lines were incomplete or AF/AFL/AT
persisted,. In case of AF, complex fractionated atrial
electrogram (CFAE) ablation was performed in the
left atrium and within the coronary sinus. CFAE was
defined as low voltage electrograms having a very
short cycle length or fractionation composed of mul-
tiple (more than 2) deflections or perturbation of the
baseline with continuous deflection of a prolonged
activation complex. CFAE detection was done by
visual inspection; automated software was not em-
ployed. Endpoint of CFAE ablation was conversion
of AF to AT/AFL or SR. If AF persisted despite exten-
sive ablation, we performed cardioversion. In case
of AT/AFL the arrhythmia was mapped and ablated.
Additionally, in all patients, the cavotricuspid isth-
mus (CTI) line was ablated, or tested for bidirectional
block if the patient underwent CTI ablation in the
past. Finally, re-induction of AF was attempted using
rapid pacing (with cycle lengths as short as 180ms) in
the coronary sinus. Upon induction of AF, we stopped
pacing and monitored the duration of AF/AFL/AT.
Additional mapping and ablation was performed if






total major complications 7 (14%) 4 (8%)
– bleeding requiring thoracotomy 2 (4%) 2 (4%)
– permanent phrenic nerve
paralysis
2 (4%) 0 (0%)
– pericardial and pleural effusion 1 (2%) 1 (2%)
– pleural effusion 1 (2%) 1 (2%)
– pacemaker implantation 1 (2%) 0 (0%)
mortality 0 (0%) –
sustained AF/AFL/AT was triggered and lasted long
enough to allow mapping it (Fig. 1).
Efficacy and safety endpoints
The primary endpoint was the first AF/AFL/AT re-
currence documented by ECG, Holter monitoring
(episode lasting more than 30s), or an event recorder
during 12-month follow-up, excluding recurrences
occurring in the first 90 days (blanking period) [14].
The secondary endpoints were safety and patient’s
quality of life. Safety was defined as the absence of
any complications as described by the 2017 expert
consensus statement on catheter and surgical abla-
tion of AF [15], quality of life assessment was assessed
using the EuropeanHeart Rhythm Association (EHRA)
score, the Toronto AF Severity Scale (AFSS) and Short
Form 36 questionnaires (SF-36).
Statistical analysis
Patient and procedural characteristics are given as
mean± standard deviation or median and interquar-
tile range for continuous variables and as number
of patients with percentages for categorical variables.
Kaplan-Meier plot and univariate cox-regression anal-
ysis were used to show and compare outcomes. Anal-
ysis was done using R package (version 3.4.3), and a p-




Tab. 1 shows the baseline clinical characteristics.
Mean age was 57± 9 years, 38 (76%) patients were
men, five (10%) had paroxysmal, 34 (68%) persistent
and 11 (22%) long-standing persistent AF. Time since
first AF diagnosis was 5.1 (2.1–8.4) years and 25 (50%)
patients had prior failed catheter ablation(s).
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Fig. 3 Kaplan-Meier plot showing outcome of the procedure.
Outcome according to: a type of AF at baseline. b duration of
longest AF episode in patients with persistent AF. c history of
catheter ablation. AF atrial fibrillation. AF atrial fibrillation
Procedural data
Tab. 2 and Fig. 2 show the procedural data. Two (4%)
patients did not undergo the endocardial procedure
due to bleeding during epicardial ablation necessitat-
ing thoracotomy. Additionally, six patients had a pace-
maker or an implantable cardioverter defibrillator and
therefore superior caval vein ablation was not per-
formed to avoid damaging the leads. In all patients,
all PVs were isolated following surgical ablation. In 27
(54%) patients, endocardial mapping demonstrated
posterior box isolation after the epicardial procedure.
In 21 (42%) patients, additional endocardial ablation
resulted in complete box isolation. In 7 (14%) of these
21 patients only the superior line was incomplete
after the epicardial procedure, in 3 (6%) patients only
the inferior line was incomplete, and in 11 (22%)
patients gaps were found in both the superior and
inferior lines. In 2 (4%) patients endocardial mapping
was not performed due to a bleeding complication
resulting in thoracotomy (see Fig. 2).
Efficacy
At 1-year follow-up, 38 (76%) patients maintained SR
following hybrid AF ablation. Recurrent atrial arrhyth-
mias occurred in 12 (24%) patients. The majority of
these recurrences (9 patients) were atypical AFL, with
the remaining 3 patients having AF recurrences. Seven
of these nine patients with AFL recurrences under-
went endocardial re-ablation, six of them completed
at least 6 months of follow-up and all six maintained
SR until their last follow-up. The seventh patient had
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Fig. 4 Scores and results
at baseline and 1 year. a Av-
erage EHRA score at base-
line and 1 year. b Results
of AF Severity Scale ques-
tionnaire at baseline and
1 year. (EHRA European
Heart Rhythm Association,
AF atrial fibrillation)
to undergo a second endocardial re-ablation due to
quick recurrence of AFL. Overall, only two (4%) pa-
tients used AADs at 1 year, both had earlier AF/AFL
recurrences (Tab. 3).
Safety
Seven (14%) patients suffered complications during
and after the procedure. Two (4%) had bleeding
during the epicardial procedure necessitating tho-
racotomy; one due to an injury to the pulmonary
artery and the other due to injury to the right inferior
pulmonary vein. Both patients recovered completely
without any sequelae. Two (4%) had permanent
phrenic nerve injury, 1 (2%) developed pericardial
and pleural effusion requiring drainage, 1 (2%) pleu-
ral effusion requiring drainage, and 1 (2%) was known
with a latent sick sinus syndrome before the proce-
dure, requiring a DDD-pacemaker after restoration of
SR. Total hospital stay was 6± 2 days (Tab. 4).
Determinants of success
Success of hybrid AF ablation showed a significant as-
sociation with type of AF at baseline (100% in parox-
ysmal AF versus 79% in persistent AF versus 55% in
long-standing persistent AF, p= 0.039; Fig. 3a and b)
and history of previous failed catheter ablation (90%
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Fig. 4 (Continued) c Re-
sults of Short Form36 ques-
tionnaire at baseline and
1 year. (EHRA European
Heart Rhythm Association,
AF atrial fibrillation)
versus 62% for patients without previous catheter ab-
lation, p=0.020; Fig. 3c).
Quality of life
The EHRA score (Fig. 4a), the AFSS questionnaire
(Fig. 4b) and the SF-36 questionnaire (Fig. 4c) at
1-year follow-up all showed significant improvement
compared with baseline, predominantly in patients
who maintained SR.
Discussion
Our study showed that in patients with previous failed
catheter ablation or persistent AF, single-stage hybrid
AF ablation was successful in 76% of patients off AADs
at 1-year follow-up. Success was significantly lower in
patients with long-standing persistent AF. Endocardial
touch-up was needed in 42% of patients to achieve
posterior box isolation. We have included posterior
box isolation as an endpoint for the procedure, be-
cause this area is more likely to harbour AF triggers or
drivers, especially in patients with persistent AF [16],
or contain substrate for re-entry, because of its prox-
imity to the pulmonary veins and its complex fibre
orientation [17]. Therefore, isolating the posterior box
may contribute to a better outcome by eliminating
these AF drivers and reducing the area of the atrial tis-
sue capable of sustaining AF. Additionally, all variants
of Maze-like procedures have posterior box isolation
as a part of their protocol [18].
Two earlier studies reported on single-stage hybrid
AF ablation in 50 patients or more. Pison et al. [12]
described 74% success off AADs in 78 patients and
Gehi et al. [19] reported a 66% success rate in 101 pa-
tients, including patients with concomitant AAD ther-
apy. Our study population was comparable with the
former study, but was younger and had less co-mor-
bidities than the latter.
Our complication rate was higher than both Pison
et al. (8%) and Gehi et al. (6%) [12, 19] reported in
hybrid ablation but lower than Boersma et al. in the
FAST trial (23%) for minimally invasive surgical AF ab-
lation [20]. Important to note here that Gehi et al. re-
ported two deaths, while no mortality was observed
in our cohort. Additionally, our complication rate was
higher than the 12% rate reported in a recent contem-
porary endocardial ablation trial (Fire and ICE) [21].
However, multiple endocardial re-ablations may also
increase the cumulative complication risk for endo-
cardial ablation.
In our analysis, type of AF was significantly asso-
ciated with success, i. e. more persistent forms of
AF were associated with poorer outcome. Our find-
ing are not unexpected since long-standing persistent
AF is associated with more extensive structural atrial
changes, driven by associated comorbidities and AF
itself [22]. This renders the ablation lines insufficient
to abolish AF due to the presence of larger atrial area
capable of sustaining AF [23]. In line with this, we ob-
served a trend towards a better outcome in patients
with a shorter episode of persistent AF. Of interest,
our analysis also showed that in patients with one
or more previous failed catheter ablations, including
both paroxysmal and persistent AF patients, hybrid
AF ablation resulted in excellent 1-year arrhythmia-
free follow-up. The success rate for longstanding per-
sistent AF was moderate but higher than reported in
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endocardial ablation studies [8, 9]. Of interest, the
majority of these recurrences were AFL episodes. En-
docardial re-ablation was highly effective, although
the follow-up period was relatively short.
Finally, quality of life assessment showed signifi-
cant improvement at 1-year follow-up, especially in
the physical parameters. This improvement was, as
expected, more pronounced in patients who main-
tained SR during the follow-up period.
Limitations
The number of patients in this analysis is still too
small to draw definitive conclusions. Additionally, due
to the lack of continuous heart rhythm monitoring
during the follow-up period, it is possible that we
failed to document some asymptomatic recurrences
of atrial arrhythmias.
Conclusion
Hybrid AF ablation is an effective treatment for per-
sistent AF or paroxysmal AF after failed catheter
ablation, but the risk of procedure-related complica-
tions should be taken into consideration. Therefore,
accurate patient selection is of utmost importance,
weighing the risks of complications against the po-
tential gain in the patient’s quality of life and the
chance of success. Patients with paroxysmal AF
after failed catheter ablation, or persistent AF with
relatively shorter AF episodes appear to be the best
candidates.
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